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OBSERVATIONS ON THE ABSORPTION, EXCRETION,
DIFFUSION, AND ACETYLATION OF
SULFADIAZINE IN MAN*
JOSEPH F. SADUSK JR., AND JOHN B. TREDWAY
Sulfadiazinet (2-sulfanilamido pyrimidine), apyrimidine deriva-
tive of sulfanilamide, has been recently synthesized by Roblin,
Williams, Winnek, and English."5 The structural formula is as
follows:
NH2
\/ H N-C-H
S02 N-C C-H
N. C H
Studies by Feinstone, Williams, Wolff, Huntington, and Cross-
ley4 on the toxicity, absorption, and chemotherapeutic activity of
this compound in mice, dogs, and monkeys indicate that it exhibits
less acute and chronic toxicity than either sulfapyridine or sulfathia-
zole. In addition, these investigators found sulfadiazine to be
readily absorbed, eliminated comparatively slowly, and acetylated to
only a small degree. Another finding worthy of note was the high
solubility of acetyl sulfadiazine in urine as compared with the solu-
bility of the acetyl derivatives of sulfapyridine and sulfathiazole.
A high therapeutic activity in experimental pneumococcal, strepto-
coccal, staphylococcal, and Friedlander's bacillus B infections in
mice was demonstrated.
Since it becomes important to determine in man the pharmaco-
* From the Department of Internal Medicine, Yale University School of Medi-
cine and the Medical Service of the New Haven Hospital.
t The sulfadiazine used in these studies was obtained through the courtesy of
Dr. David A. Bryce, Lederle Laboratories, Inc.YALE JOURNAL OF BIOLOGY AND MEDICINE
logical properties of the newly introduced sulfonamide drugs after
animal studies have been carried out, observations are recorded in
thispaper on the absorption, excretion, diffusion into body fluids, and
acetylation of sulfadiazine in man. These studies were made in
part on individuals not receiving chemotherapeutic treatment, in part
on patients with acute infections, mostly pneumococcal pneumonia
undergoing therapy with sulfadiazine.
Previous studies on the absorption and excretion of sulfadiazine
in man, made by Plummer and Ensworth,"2 indicate that this drug
is rapidly absorbed into the blood stream following oral ingestion of
the drug. They obtained comparatively high blood concentrations,
with the level falling more slowly than with sulfathiazole but some-
what more rapidly than with sulfapyridine. Conjugation of sulfa-
diazine was low. In two cases, wherein urinary excretion was
followed for a sufficiently long period, approximately 80 per cent of
the ingested drug was excreted by the kidneys.
Very recently, Reinhold and his associates"4 have confirmed the
above findings for man andpresent further data onthe urinary excre-
tion and diffusion into the various body fluids. They found that 47
to 85 per cent of sulfadiazine was excreted by the kidney within 48
hours following a single oral dose of 3 grams. Sulfadiazine was
found to penetrate readily into the pleural and peritoneal cavities,
and 24 hours after the administration of an initial dose the cerebro-
spinal fluid contained appreciable quantities of the drug.
Materials and methods
Observations on the rate of absorption of sulfadiazine from the gastro-
intestinal tract, as measured by frequent determinations of blood concentra-
tion following a single oral dose of 0.06 gm./K per os, were made twice in
each of two normal males and compared with the data obtained following two
similar intravenous doses of sodium sulfadiazine in another individual. In
addition, in order to provide information on the range of individual variation,
the blood concentration attained 4 hours after a single initial oral dose of 4.0
gm. of sulfadiazine was determined in 24 patients.
Nine studies on the excretion of sulfadiazine in the urine, either following
a single dose of 0.06 gm./K or an initial dose of 4.0 gm. per os followed by
1.0 gm. every 6 hours, were conducted in 7 individuals over varying periods
of time.
The rate and amount of diffusion of sulfadiazine into body fluids, as
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measured by simultaneously determined blood concentrations, were studied
in 22 instances, either after a single dose of 4.0 gm. of sulfadiazine given
orally or an initial dose of 4.0 gm. followed by 1.0 gm. every 6 hours. Four
of these observations were on pleural effusions, three on ascitic fluids from
cases of hepatic cirrhosis, and 16 were on non-inflammatory spinal fluids from
patients receiving diagnostic lumbar puncture. Of the last group, 3 patients
received a single intravenous dose of 3 to 4 gm. of sodium sulfadiazine.
In the collection of pleural and spinal fluids ethyl chloride was used as a
local anesthetic in order to avoid error from the presence of novacaine, as pre-
viously noted in our studies on sulfathiazole.16 Adequate precautions were
also observed in the collection of ascitic fluids.
In order to determine the range of variation in blood concentration that
may occur in patients under continued treatment with sulfadiazine, daily
blood determinations were made just prior to the 8:00 A. M. dose in a series
of patients, some with pneumococcus pneumonia, others undergoing chemo-
therapeutic study. The results in 38 cases, in whom the treatment consisted
of an initial dose per os of 4.0 gm. followed by 1.0 gm. q. 6 h. for varying
periods of time, are presented.
In all the foregoing observations the concentration of both free and total
sulfadiazine was determined, thus providing a mass of material on the degree
of acetylation which occurs in man.
The method of Bratton and Marshall,3 using N-(1-napkthyl)ethylene-
diamine hydrochloride as the coupling component, was used in determining
the concentration of sulfadiazine in blood, urine, and body fluids. Readings
were made with the Evelyn photoelectric colorimeter, using the 10 cc. aper-
ture and No. 540 filter. A 1: 80 dilution of blood and body fluids and
appropriate dilutions of urine were employed. The only other deviations*
from the method of Bratton and Marshall were (1) the substitution of an
0.033 N solution of sodium nitrite in place of 0.1 N sodium nitrite, and (2)
the use of 0.5 cc. of 8 N HCI with heating for 30 minutes in the boiling
water-bath for determination of the conjugated fraction. These modifica-
tions gave results with a maximum minus error of less than 10 per cent.
OBSERVATIONS
Absorption of sulfadiazine
The rate of absorption of sulfadiazine in two normal adult males
following single oral doses of 4.7 and 4.2 gm. (0.06 gm./K body
*The authors are indebted to Miss Pauline M. Hald who has modified the
method of Bratton and Marshall and under whose direction the determinations of
sulfadiazine were carried out.
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OBSERVATIONS ON THE BLOOD CONCENTRATION AND URINARY EXCRETION OF
SULFADIAZINE FOLLOWING THE INGESTION OF A SINGLE DOSE per os OF
0.06 GM./K BODY WEIGHT IN TWO PATIENTS
Howrs Blood Urine
after
Subject Exp. Dose adminis- Sulfadiazine Sulfadiazine excreted
tration Free Total Acet. Volume Free Total Acet. Recovered
gm. mgm.A% mgmn.% % cc. gm. gm. % %
J.T. 1 4.7 0
Y2 0.5 0.7 29 Normal 1 1.5 1.5
2 3.4 3.7 8
3 4.1 4.5 9
4 4.1 4.6 11
6 3.2 3.8 16 540 0.35 0.46 24 9.7 -
8 2.9 3.6 19
12 1.8 2.3 22 360 0.31 0.52 40 11.0 20.7
18 1.2 1.6 25 235 0.11 0.21 48 4.4 25.1
24 0.9 1.2 25 290 0.11 0.23 53 4.8 29.9
48 0.4 0.4 - 1340 0.25 0.43 41 9.2 39.1
J. T. 2 4.7 0
Y2 1.0 1.3 23
Normal 1 2.1 2.3 9
2 3.7 4.1 10
3 4.9 5.6 13
4 4.7 5.5 15
6 3.9 4.4 11 650 0.55 0.64 13 13.6 -
12 2.3 2.4 4 440 0.43 0.58 27 12.3 25.9
18 1.4 1.8 22
24 1.0 1.3 23 830 0.21 0.37 44 7.9 33.8
4$ 0.5 0.5 - 630 0.11 0.20 47 4.3 38.1
J. S. 3 4.2 0
Y2 0.9 0.9
Normal 1 1.7 1.7
2 3.2 3.3 3
3 3.1 3.5 11
4 3.3 3.7 11
6 3.2 3.8 16 372 0.25 0.32 20 7.6 -
12 2.1 2.4 13 340 0.24 0.58 59 13.8 21.4
18 1.5 1.7 12 590 0.15 0.46 68 11.0 32.4
24 1.3 1.5 13 325 0.10 0.18 42 4.3 36.7
36 0.9 0.9 - 760 0.15 0.24 38 5.7 42.4
48 0.4 0.4 - 460 0.06 0.08 28 1.9 44.3
J.S. 4 4.2 0
Y2 1.5 1.6 6
Normal 1 2.1 2.3 9
2 3.4 3.6 6
3 4.8 5.3 10
4 5.3 6.2 15
6 5.8 6.4 9 395 0.37 0.52 30 12.3
8 5.8 6.4 9
12 5.5 6.2 11 348 0.45 0.70 35 16.7 29.0
18 3.8 4.6 17 420 0.35 0.62 43 14.8 43.8
24 2.7 3.1 13 350 0.23 0.46 50 11.0 54.8
48 0.7 0.7 1440 0.37 0.76 51 18.1 72.9BEHAVIOR OF SULFADIAZINE IN MAN
weight), respectively, is shown in Table 1, with one of these experi-
ments (No. 1) being graphically illustrated in Fig. 1. Each indi-
vidual was subjected
to two experiments 9 SILESNLE ZSEO \ 1800oo in order to demon- 8 \ xnz.!4a-7
strate the variation x x o
that occurs in the e- zt
sameperson,inaddi- 6o0o
tion to the variation c Olx -
that is ordinarily 84 - 800L
seenwithinagroup. 103 - - 60
The blood concen- 2 ,4O
trations of sulfadia- I200
zine obtained at c ,_
varying intervals 0 234 6 8 2 18 24
after the single dose FIG. 1. Concentration of total and free sulfadiazine in the
were averaged to blood and the urinary excretion following a single dose of sulfa-
diazine orally in a normal adult male (Exp. 1, Table 1). The clear give a composite and solid circles represent the total and free blood sulfadiazine
view of the blood respectively; the clear and solid vertical columns represent the increments of acetylated and free sulfadiazine excreted in the
curve in the four ex- urine; and the dotted lines represent the cumulative excretion of
periments. This is total and free sulfadiazine in the urine.
illustrated by
Fig. 2. AVERAGE BLOOD CONCENTRATION
It will be OF S 0ADIAZINE AFTER OE ORAL DOSE lt wlll ue S7 ~~~~~0.06GM./K,6M.
noted that the .
peak of concen- X':
tration occurred .
in from 3 to 6 S
hours after in- D
gestion, with the ,
average peak be- uc .l
ing at 4 hours. 01234 6( 12 18 24 36 48
The drug con- ~ ~~~~~~HOURS The drug con- FiG. 2. Average blood concentrations of total and free sulfadiazine
centration then following a single oral dose of 0.06 gm./K body weight of sulfadiazine.
f The curve is made up by averaging a total of 4 experiments, complete fell relatively slowly,
a
t ae
ydata on which are given in Table 1.
slowly, with a
not inconsiderable concentration being present 24 hours after admin-
istration, and from 0.4 to 0.7 mgm. per cent sulfadiazine still being
found in the blood 48 hours after administration. This indicates
readyabsorption, fairlycomparable to but somewhat slower than that
of sulfanilamide and sulfathiazole, but with an apparent slow rate
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ofexcretion, reminiscent ofsulfapyridine. Since the curve represents
a composite of absorption, diffusion, and excretion, it should be
nloted that only 7.6 to 13.6 per cent of the ingested drug was
excreted during the first 6-hour period. This is in decided contrast
to the excretion of sulfathiazole"6 noted in our previous studies, and
will be commented on later.
Absorption of sulfadiazine from the gastro-intestinal tract may
be expected to vary considerably from individual to individual, as
shown with sulfapyridine2 and sulfathiazole." The results of
observations on blood concentration 4 hours after an initial dose of
4.0 gm. of sulfadiazine in 24 cases, of whom 8 had pneumococcal
pneumonia and the remainder had miscellaneous conditions not
under treatment, are shown in Table 2. The concentrations found
TABLE 2
VARIATIONS IN CONCENTRATION OF SULFADIAZINE IN THE BLOOD 4 HOURS AFTER A
SINGLE ORAL DOSE OF 4.0 GRAMS OF SULFADIAZINE IN 24 CASES
Totalsulfadiasine No. of cases
mgm. %
0.0-0.9 ........................... 1
1.0-1.9 ........................... 2
2.0-2.9 ........................... 3
3.0-3.9 ........................... 4
4.0-4.9 ........................... 5
5.0-5.9 ........................... 2
6.0-6.9 ........................... 4
7.0-7.9 ........................... 2
8.0-8.9 ........................... 1
0.9-8.0 ........................... 24
ranged from 0.9 to 8.0 mgm. per cent, the majority falling between
2.0 and 4.9 mgm. per cent. These figures obviously indicate a con-
siderable individual variation in the rate of absorption of sulfadiazine
and are comparable to similar variations found with sulfapyridine
and sulfathiazole. That absorption may be especially poor in the
presence of disease is indicated by the fact that the 3 lowest concen-
trations found, all below 2.0 mgm. per cent, were obtained from
patients with lobar pneumonia who were severely ill.
For comparison, the curve of blood concentration following a
single intravenous dose of 3.0 gm. (0.06 gm./K body weight) of
sodium-sulfadiazine is illustrated in Fig. 3 and the results of two
such experiments on the same person are offered in Table 3.
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Excretion ofsulfadiazine
Observations on the excretion of sulfadiazine in the urine in two
normal adult males following a single oral dose of 4.7 and 4.2 gm.
(0.06 gm./K body weight), respectively, are shown in Table 1,
with one of
the experiments 11
V.DO 6E 22 (No. l)beingil- 11, O OmAZINE - 220
lustrated graph- 10 2000
W
ically in Fig. 1. le9 /, 1,00r
For comparison, 8 / 160
the data of simi- 40 .7 - - 1400 lar studies in an- o J- '.'10
other normal 86 -- 00
adult male fol- 05 , 800
lowing a single 4 //800 c
I'~~~~~~~~~~~~~~~~~~~~~~~I intravenous dose gd 600-
of sodium sul- 2t If 400 fadiazine are 0 'r
shown in Table
3with oneofthe ° 6 8 12 1 24 0
experiments be- HOURS
ing graphically FIG. 3. Concentrations of total and free sulfadiazine in the blood
*i11ustrate,1i* and the urinary excretion following a single dose (0.06 gm./K) intra-
lllustrated in venously of sodium sulfadiazine in a normal adult male. The clear and
Fig. 3. It will solid circles represent the total and free blood sulfadiazine, respectively;
be seen that the the clear and solid vertical columns represent the increments of acetylated
and free sulfadiazine excreted in the urine; and the dotted lines represent
urinaryexcretion the cumulative excretion of total and free sulfadiazine in the urine.
of sulfadiazine
following intravenous injection of the sodium salt is more quantita-
tive and more regular than that seen with oral ingestion of sulfa-
diazine itself. In 6 hours, approximately 42 per cent of the
sulfadiazine administered intravenously was excreted in the urine as
contrasted with an excretion of 8 to 14 per cent during a similar
period when the acid salt had been taken per os. Similarly, during
a 24-hourperiod, 73 to 76 per cent oftheintravenously administered
drug was excreted, in comparison to a 30 to 55 per cent excretion of
the ingested drug. In addition, the peak of excretion of the orally
administered sulfadiazine was ordinarily found in the second 6-hour
period, while the peak found with the intravenous salt was during
the first 6-hour period. These facts, when compared with previous
data on sulfathiazole,16 would indicate that sulfadiazine is absorbed
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and excreted somewhat more slowly than is sulfathiazole. These
facts are probably an important factor in the explanation for the
maintenance of a sustained blood concentration of sulfadiazine over
longer periods of time than is the case with sulfathiazole.
In order to obtain information concerning variations in the
TABLE 3
OBSERVATIONS ON THE BLOOD CONCENTRATION AND URINARY EXCRETION OF SULFA-
DIAZINE FOLLOWING THE INTRAVENOUS INJECTION OF A SINGLE DOSE OF 3.0 GRAMS
(0.06 GM./K BODY WEIGHT) OF SODIUM SULFADIAZINE IN THE SAME PATIENT
Hours Blood Urine
after
admin- Sulfadiazine Sulfadiazine Excreted
Subject istration Free Total Acet. Volume Free Total Acet. Recovered
mgm. mgm. % cc. gm. gm. % %
% %7
W,W. 0
Y4 8.7 9.2 5
1I/4 7.8 8.6 13
Normal 2',4 6.7 7.7 13
4 5.4 6.2 13
6 1310 1.04 1.25 17 41.7 -
8 3.0 3.8 21
12 1.8 2.2 18 1460 0.47 0.59 19 19.7 61.4
18 1040 0.21 0.26 20 8.7 70.1
20 0.6 0.8 25
24 0.5 0.6 17 820 0.06 0.10 56 3.3 73.4
W.W. 0
2 11.7 11.7 -
1 10.6 11.3 6
Normal 2 8.6 9.1 6
3 7.7 8.3 7
4 6.1 6.1 -
8 4.1 4.3 5
12 2.0 2.2 9
24 1.0 1.0 - 2460 1.73 2.28 24 76.0 -
36 0.4 0.4 -
48 0.0 0.0 _ 2550 0.12 0.23 48 7.7 83.7
amount of sulfadiazine excreted in the urine in cases under con-
tinued treatment, similar observations were made in 5 patients who
received the drug over periods of time ranging from 1 to 4 days.
I'he summarized data are shown in Table 4, from which it will be
seen that the amount of administered drug recovered in the urine
was surprisingly constant.BEHAVIOR OF SULFADIAZINE IN MAN
Diffusion into body fluids
Data concerning the rate and degree of diffusion into pleural
and ascitic fluids are shown in Table 5. In three observations 4
hours after an oral dose of 4.0 gm. of sulfadiazine the concentration
of total sulfadiazine in the fluids varied between 24 and 68 per cent
TABLE 4
EXCRETION OF SULFADIAZINE IN THE URINE OF PATIENTS RECEIVING AN INITIAL
DOSE OF 4.0 GM. FOLLOWED BY 1.0 GM. Q. 6 H.
Sulfadiazine
Clinical Administered Blood Recovered in Urine
Case diagnosis Length Maxinum
Total ofadmin. Concentration Length of % of Acetylated
dose istration Free Total excretion total dose daily
gm. mngm. mgm.
A. A. Muscular % % %
dystrophy 7.0 18 hrs. 8.3 9.1 24 hrs. 55.6 25
48 hrs. 57.4
72 hrs. 61.3
C. T. Lobar 21.0 4 days 9.0 102 5 days 62.8 13-25
pneumonia 6 days 68.2
7 days 70.1
J. H. Brain 15.0 3 days 6.9 7.5 4 days 62.7 18-31
tumor 5 days 66.3
M. F. Carcinoma 15.0 3 days 11.1 12.2 4 days 56.0 23-33
of sigmoid 5 days 63.4
W.Wa. Arterio- 15.0 3 days 7.3 7.5 4 days 62.9 12-24
sclerotic
heart disease
of the blood concentration. At this time, however, only free sulfa-
diazine had entered the fluids. At 16 to 24 hours after the initial
dose, however, the total sulfadiazine concentration in the pleural
fluids had reached levels of from 102 per cent (the minimum) to
137 per cent of that in the blood, with conjugated sulfadiazine now
being present in amounts ranging from 2 to 12 per cent of the total.
The degree ofdiffusion into ascitic fluid was somewhat less, with the
sulfadiazine concentration ranging from 48 to 77 per cent at the end
of a 24-hour period. Conjugated sulfadiazine was present in
amounts from 0 to 8 per cent of the total.
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These observations indicate that sulfadiazine diffuses readily and
at a fairly rapid rate into pleural and ascitic fluids, the results being
essentially similar to those obtained with sulfapyridine and sulfa-
TABLE 6
DIFFUSION OF SULFADIAZINE INTO CEREBROSPINAL FLUID
Dosage Sulfadiazine
gin.
Hours Blood Spinal Fluid
after Per cent Ceta
Case Drug* Initial Subsequent dose of blood system
cone.
Free Total Free Total (total)
mgm. MgnL mgm. mgm.
% % % %
W. J. SD 4.0 _ 4 4.1 4.1 0.5 0.5 12 Epilepsy
M. C. SD 4.0 4 7.3 7.7 0.2 0.2 3 Epilepsy
L. S. SD 4.0 1.0q.6h.(3x) 4 8.0 8.0 0.8 0.8 10 Multiple
sclerosis
24 6.2 6.8 3.5 3.5 52
J. J. SD 4.0 1.0q.6h.(3x) 4 4.1 4.1 0.6 0.6 15 Normal
24 8.1 9.0 4.8 4.8 53
L. M. SD 4.0 1.0q. 6h.(lx) 8 8.4 9.2 1.6 1.6 17 Normal
J. H. SD 4.0 1.0 q. 6h.(lx) 12 5.2 5.7 1.0 1.0 - 18 Brain tumor
(normal
C. S. F.)
A. G. SD 4.0 1.0q. 6h.(lx) 12 4.1 4.4 1.4 1.4 32 Normal
T. F. SD 4.0 1.0q. 6h.(2x) 18 7.3 8.4 3.1 3.1 37 Normal
J. D. SD 4.0 1.0q.6h.(2x) 18 4.6 5.1 2.0 2.0 39 Normal
E. W. SD 4.0 1.0q. 6h.(2x) 18 5.1 5.7 3.6 3.6 63 Cerebral
thrombosis
A.A. SD 4.0 1.0q.6h.(3x) 24 8.3 9.1 4.6 4.7 52 Muscular
dystrophy
A. H. SD 4.0 1.0q.6h.(3x) 24 8.4 9.3 3.9 3.9 42 Normal
M. P. SD 4.0 1.0q.6h.(17x) 96 9.0 9.7 4.7 4.7 49 Normal
W. W. NaSD** 3.0 4 6.1 6.1 1.1 1.1 18 Normal
J. C. NaSD** 4.0 4 11.2 12.1 2.6 2.6 22 Cerebral
thrombosis
E. O'B.NaSD** 4.0 4 11.8 12.8 2.1 2.1 16 Syphilis
*NaSD = Sodium sulfadiazine; SD = Sulfadiazine.
**Administered intravenously.
thiazole. Since it has been demonstrated that sulfathiazole does not
diffuse readily into the non-inflammatory16 and inflammatory18 20
spinal fluid, information concerning the diffusion of a newly intro-
duced sulfonamide drug into the spinal fluid is of importance in rela-
tion to the treatment of meningitis. Studies of this problem were
conducted with sulfadiazine in 13 patients and with sodium sulfa-
diazine in 3 patients, none of whom had evidence of acute inflamma-
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tion of the meninges. No opportunity to make observations in cases
ofacutemeningitis has as yet presented itself. The results are shown
in Table 6. In 4 observations made at 4 hours after an initial oral
SULFADIAZINE dose of 4.0 gm. of
8 _ < ° 8 sulfadiazine, it was
found that the total
6- // 6 sulfadiazine concen-
4 - @ + tration ranged from
-<- ~3 to 15 per cent of
2 §,,' 2 that in the blood.
X 2 I62 i4 With continued
0 4-6 1 16 20 24°treatment, the con-
SULFATHIAZOLE SULFAR"INE 8 centration of the o SPINIALFLUDULL v drug in relation to
6 > = / / 6 the blood concentra- !:!4 | _,:S5' tion steadily in-
-l::-- creased, as measured
P. by determinations at
8, 12, 18, 24, and 1 -06 z4 o 4 t 2 1- 20 240 96 hours after the
HOURS OF THERAPY
FIG. 4. Comparison of diffusion of sulfapyridine, sulfathiazole, initial dose. At the
and sulfadiazine into spinal fluid in individual patients. Dosage in 24-hour period, the
grams; blood and spinal fluid levels in mgm. per cent. Clear
circles = total sulfonamide; solid circles = free sulfonamide. sulfad,azie concen-
tration in the spinal
fluid ranged from 42 to 53 per cent of that of the blood. No con-
jugated sulfadiazine was present.
These observations indicate that sulfadiazine diffuses fairly well
into the non-inflammatory cerebrospinal fluid within 12 to 18 hours,
though at a slower rate and at a somewhat lower concentration than
sulfanilamide and sulfapyridine. A comparison of sulfadiazine,
sulfathiazole, and sulfapyridine is shown in Fig. 4.
Experiments carried out with the intravenous injection of a
similar quantity of the sodium salt of sulfadiazine, as shown in
Table 6, indicate that the relative concentration of spinal fluid sulfa-
diazine as compared with blood sulfadiazine after 4 hours is only
slightly greater than in the experiments following the administra-
tion of sulfadiazine per os. However, it should be noted that the
actual concentration of the drug itself in the spinal fluid is much
higher with the intravenous injection of the sodium salt. This fact
at once suggests the desirability of using the sodium salts of the
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sulfonamide compounds intravenously in the initial treatment of
acute meningitis.
Variations in blood concentration under continued
treatment ith sulfadiazine
It has been shown above that there is considerable variation in
absorption of sulfadiazine from the gastro-intestinal tract following
a single dose of the
drug, a factwhich might I -
be expected to result in 12 O ° 8
variations in blood con- SII o 8
centration from patient 1, .
to patient under con- B
tinued treatment with a
J 8 * *
standard dosage of the
'
:v
drug. That this expec- co 8 0 O
tation is borne out is O 8
shown in Fig. 5, in 3 O O O
which daily determina- 28
tions of the concentra-
tion oftotal sulfadiazine % I
' 20 24 3 4 5 6 7
in the blood of 38 pa- HOURS DAY OF THERAPY
tients under treatment FIG. 5. Variations in blood concentration of total sulfa.
, ., 111 diazine in patients under continued treatment. Median is
isgraphicallylluustrated. shown by large circles.
In this series are in-
cluded 12 patients with pneumococcal lobar pneumonia, two patients
with miscellaneous infections, and 24 patients undergoing chemo-
therapeutic study. The dosage employed in those patients under
continuous treatment consisted of an initial dose of 4.0 gm., followed
by 1.0 gm. q. 6 h. No cases with renal disease or marked congestive
heart failure are induded. The 4-hour blood concentration deter-
minations were made on samples of blood collected 4 hours after the
initial dose of 4.0 gm. and 2 hours prior to the first 1.0 gm. dose of
the maintenance treatment. All other determinations were made on
samples of blood collected at approximately 8:00 A.M., 6 hours
after the regular 2:00 A. M. dose of 1.0 gm. and just before the
8:00 A. M. dose. The day on which therapy was begun was con-
sidered the first day of treatment, irrespective of the time that sulfa-
diazine was started, the second day of treatment beginning at 7:00
A. M. on the following day, and so on.
The data recorded in Fig. 5 show awidevariation inblood levels
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both during the early hours of treatment and by the third day and
later, though in general from the third day on a probable satis-
factorytherapeutic level is obtained in nearly all cases. The median
TABLE 7
OBSERVATIONS ON THE BLOOD CONCENTRATION OF SULFADIAZINE AT VARYING
INTERVALS AFTER STOPPING THE DRUG
Sulfadiazine
Days Hours after last dose of drug Sutbiect on Blood conc.
drug at lastdose 18 24 48
Free Total Free Total Free Total Free Total
mgm. mgm. mgm. mgm. mgm. mgm. nIgm. mgm.
% Y %Y %1 % % % %11
A. H. 1 8.4 9.3 4.6 5.2
M. F. 3 11.1 12.2 62 6.9
J. H. 3 6.9 7.5 3.8 4.3
A. T. 5 7.3 7.9 1.3 1.3
B. C. 5 4.0 6.6 1.6 2.0
J.McQ. 5 4.4 4.6 1.3 1.8
C.J. 5 9.0 102 4.6 5.0 1.9 2.1
M. C. 6 10.4 11.4 4.1 4.8 0.9 1.0
J. T. 6 6.9 10.6 2.7 5.3 - 0.9 1.8
W.B. 7 5.7 6.2 2.0 2.2 0.5 0.5
level would appear to be higher than that obtained with sulfathia-
zole16 from the third day of therapy and on.
In a number of patients in this series, determinations of the con-
centration ofsulfadiazine inthebloodwere made at various intervals
after the last dose of the drug had been given. These observations
are recorded in Table 7 and demonstrate that not inconsiderable
concentrations of sulfadiazine may be present 18 and 24 hours after
discontinuance of the drug. Indeed, concentrations of 0.5 to 2.1
nigm. per cent of total sulfadiazine were found even 48 hours later.
Since none of these cases exhibited evidences of renal functional
impairment or congestive cardiac failure, conditions which may
seriously affect the renal excretion of sulfathiazole,16 these observa-
tions further support the views that sulfadiazine is less rapidly
excreted than is sulfathiazole.
Acetylation of sulfadiazine
The importance of acetylation of the sulfonamide compounds is
well known. Not only is the conjugated form therapeutically inac-
tive but also by virtue of its high insolubility in urine it fosters the
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production of hematuria and anuria, as has been repeatedly reported
in sulfapyridine"7 19 and sulfathiazole5 6'7'11 therapy.
The degree of acetylation of sulfadiazine has been studied from
day to day in a series of patients. As representative of the group the
data on the same
patients included in 35
Fig. 5 are shown in
Fig. 6, which re- _J .
0 cords the daily per 'a °
cent of the total w ao
sulfadiazine in the b.vo J
blood that was acet- dv
ylated. It will be 2 0 3 ; 5
seen that the degree HOURS DAY OF THERAPY
of acetylation, with FIG. 6. Daily observations on the percentage of acetylated sulfa-
few exceptions, falls diazine in patients under continued treatment. Same cases as those
within the relatively of Fig. 5.
narrow range between 0 and 20 per cent, the median being approxi-
mately 9 per cent. The conjugation of sulfadiazine in man, there-
fore, is lower than that of sulfanilamide,10 21 sulfapyridine,1 2,22 or
sulfathiazole.7' 13 16
Reference to Tables 1, 3, and 4 will show that the percentage of
acetylated sulfadiazine found in the urine tends to be somewhat
higher than is the case with sulfathiazole.1' This may possibly be
related to the greater solubility of the acetyl derivative of sulfa-
diazine in urine, as demonstrated by Feinstone and his associates.4
Analysis of the data in Table 5 indicates that acetylated sulfa-
diazine does not diffuse so rapidly into pleural and ascitic fluids as
does free sulfadiazine, only free drug being present in the 4-hour
specimens when the acetyl compound was already present in the
blood. It has already been pointed out that only free sulfadiazine
was found in spinal fluids, even as long as 24 to 96 hours after the
initial dose of the drug was administered.
Discussion
The foregoing observations on the pharmacological properties of
sulfadiazine indicate that absorption of the drug is sufficiently rapid
to yield satisfactory blood concentrations within 4 to 6 hours after
an initial dose of 4.0 gm. in the average case and that an appropriate
blood level may be obtained by 12 hours and later in the great
majority of cases with a maintenance dose of 1.0 gm. every 6 hours.
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Though no opportunity has presented itself to study the blood
concentration curve in patients with impaired renal function or con-
gestive cardiac failure, such dosage would doubtless be excessive
judging from previous experience with sulfathiazole,16 and might
result inundesirablyhigh concentrations ofsulfadiazine. The dosage
in such patients, therefore, should be regulated by careful attention
to thebloodlevel. The inadequate absorption of sulfadiazine within
4 hours, in certain patients, particularly in those who are severely
ill, demonstrates the necessity for the intravenous use of the sodium
salt in selected cases. Marshall and Longe have likewise called
attention to the use of sodium sulfapyridine in similar instances.
In agreement with others it has been demonstrated that sulfa-
diazine is conjugated to only a small degree; hence, the necessity for
determining the conjugated drug may be eliminated for routine
purposes.
Though the urinary concentration of the acetylated derivative
tends to be somewhat higher with sulfadiazine than with sulfathia-
zole, the greater solubility of the former in urine would possibly
lead one to believe that the drug may not produce calculi in the
urinary tract of man. Experimental evidence in support of this pos-
sibility hasalreadybeenprovidedbyFeinstone and his collaborators,4
who found no postmortem urinary calculi or histological changes in
the kidneys of monkeys treated with sulfadiazine, except in those
animals which were on an extraordinarily high dosage of the drug.
In addition, we have found it unusually difficult to find crystals of
acetylated sulfadiazine in the urine of patients under study, even
after chillingthe urine for several hours in the ice-box. In only one
case have sheaf-like crystals been found in the urine and then only
after chilling and in such small numbers that it was impossible to
collect a sample for chemical analysis. The crystals were essentially
similar in appearance to those of acetylated sulfathiazole,1 resem-
bling bound sheaves of wheat.
The ready diffusion of sulfadiazine into pleural and ascitic fluids
suggests the probable efficacy of this compound in the early stages of
suitable infection of these body cavities. The rather slow rate of
diffusion into the spinal fluid on the other hand suggests the desira-
bility of the initial use of the sodium salt of sulfadiazine intrave-
nously in the treatment of meningeal infections.
We have not had sufficient experience with sulfadiazine to offer
any statistics on its toxic manifestations. Suffice it to say, however,
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that in 16 patients receivingthe drug for periods of from 3 to 8 days,
and in 24 patients receiving the drug for aperiod ofless than 3 days,
only two toxic reactions have been seen. In one instance, a patient
experienced vertigo during the first 16 hours, which disappeared
despite maintenance of therapy. The second patient, a 69-year-old
woman with a pneumococcus Type III otitis media, developed drug
fever without skin eruption on the 6th day of therapy. The maxi-
nium temperature was 1020 F. and the temperature was normal
within 72 hours after discontinuance of the drug. In not a single
instance was nausea or vomiting observed, and no effects on the
hemapoietic or urinary systems were encountered.
Summary
Observations on the absorption, excretion, diffusion, and acetyla-
tion of sulfadiazine in man have been presented. They show (1)
that sulfadiazine is readily absorbed in most instances but is not
rapidly excreted; (2) that there is considerable individual variation
in capacity to absorb the drug, though not enough to interfere with
the use of a standard dosage in the majority of patients; (3) that
sulfadiazine readily diffuses into pleural and ascitic fluids and at a
somewhat slower rate into the cerebrospinal fluid; (4) that acetyla-
tion of sulfadiazine in the blood is only slight, rarely exceeding 20
per cent, but is somewhat higher in the urine though rarely sufficient
to cause precipitation of crystals, presumably because of its relatively
high solubility; and (5) that limited experience with the drug sug-
gests a low degree of toxicity. Finally, some of the clinical implica-
tions of these observations on the pharmacological properties of
sulfadiazine have been briefly discussed.
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